Fractyl Health, Inc. (GUTS)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $4.03
- As of
Kresmion compiles this page from GUTS's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
FRACTYL HEALTH, INC. (GUTS): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-01.
See the full GUTS dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for GUTS on one page. Preview it with sample data, then open it live with a free account.
Preview the GUTS dossierActive signals for GUTS
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 12.9%, EPS $-0.12 vs $-0.1377 estimate
- highINSTITUTIONAL_SURGE
RENAISSANCE TECHNOLOGIES LLC added +247% to GUTS (2026Q2)
- highINSTITUTIONAL_EXIT
TWO SIGMA INVESTMENTS, LP cut 53% of GUTS (2026Q2)
- highINSTITUTIONAL_EXIT
RENAISSANCE TECHNOLOGIES LLC cut 98% of GUTS (2026Q1)
- highINSTITUTIONAL_EXIT
TWO SIGMA INVESTMENTS, LP cut 74% of GUTS (2026Q1)
FREE, NO ACCOUNT
Every signal on GUTS, as it fires
You are seeing 5 of 9 signals recorded on GUTS since 2026-05-16.
The five above landed across 3 days. The other 4 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in GUTS (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 35168W103 · 2026Q2 | $178K | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 35168W103 · 2026Q2 | $97K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, GUTS
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
GUTS against its peers
GUTS's return on equity of -1490.3% ranks in the 7th percentile of 21 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-06-30.
| Metric | GUTS | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 0.0 USD | 800000 USD | 9 | 15 |
| Operating margin | n/a | -5743.5% | n/a | 13 |
| Net margin | n/a | -5570.6% | n/a | 13 |
| Return on equity | -1490.3% | -102.4% | 7 | 21 |
| 1 year | -75.0% | -49.5% | 20 | 21 |
Peers (25): LONA, PDSB, EXOZ, ALDX, CELU, INMB, IBIO, SER, ATHE, HYPD, ANVS, GOSS, CNTB, DWTX, MREO, CRBU, XLO, TIL, TENX, CRVO, BOLD, ELTX, AURX, IMA, ACET. Fiscal periods ending between 2025-06-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (GUTS: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow GUTS on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to GUTS for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.